Skip to main content

Lilly Value Stock - Dividend - Research Selection

Eli Lilly and Company

ISIN: US5324571083, WKN: 858560

Market price date: 13.11.2020
Market price: 142,38 USD




Eli Lilly and Company Fundamental data and company key figures of the share

Annual reports in USD
Key figures 21-02-2020
Cash flow
Net operating cash flow 4.836.600.000
Capital Expenditures -1.033.900.000
Free cash flow 3.802.700.032
Balance sheet
Total Equity 2.606.900.000
Liabilities & Shareholders equity 39.286.100.000
Income statement
Net income 4.637.900.000
Eps (diluted) 4,960
Diluted shares outstanding 935.684.000
Net sales/revenue 22.319.500.000

Fundamental ratios calculated on: 13-11-2020

Ratios
Key figures 13-11-2020
Cash flow
P/C 27,55
   
P/FC 35,03
Balance sheet
ROI11,81
ROE6,64
Income statement
P/E28,71
Div. Yield0,00%
P/B51,10
P/S5,97


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolLLY
Market Capitalization131.959.513.088,00 USD
CountryUnited States
IndicesS&P 500
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split1997-10-17,2.0000/1.0000; 1997-10-16,2.0000/1.0000; 1995-12-22,2.0000/1.0000; 1995-12-21,2.0000/1.0000; 1989-05-02,2.0000/1.0000; 1989-05-01,2.0000/1.0000; 1986-01-31,2.0000/1.0000; 1986-01-30,2.0000/1.0000
Internetwww.lilly.com


Description of the company

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer\'s disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.lilly.com